1	Comparison of dried blood spots and venous blood for the detection of SARS-CoV-2
2	antibodies in a population of nursing home residents.
3	Eline Meyers ^{1*} , Stefan Heytens ^{2*} , Asangwing Formukong ¹ , Hanne Vercruysse ³ , An De Sutter ² ,
4	Tom Geens ³ , Kenneth Hofkens ¹ , Heidi Janssens ³ , Eveline Nys ⁴ , Elizaveta Padalko ^{1,4} , Ellen
5	Deschepper ⁵ , Piet Cools ^{1#}
6	
7	¹ Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent
8	University, Ghent, Belgium
9	² Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences,
10	Ghent University, Ghent, Belgium
11	³ Research and analytics, Liantis Occupational Health Services, Bruges, Belgium
12	⁴ Laboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium
13	⁵ Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
14	
15	
16	Running Title: Dried blood spots for SARS-CoV-2 serology.
17	
18	*Both authors contributed equally to this work. Author order was determined in order of
19	increasing seniority.
20	*Corresponding author: Prof. Dr. Piet Cools, piet.cools@ugent.be
21	
22	
23	
24	

25 Abstract

26 Introduction

27 In the current SARS-CoV-2 pandemic, testing for SARS-CoV-2 specific antibodies is 28 paramount to monitor immune responses in post-authorization vaccination and sero-29 epidemiology studies. However, large scale and iterative serological testing by venipuncture 30 in older persons can be challenging. Capillary blood sampled using a finger prick and collected 31 on protein saver cards, i.e., dried blood spots (DBS), has already proven to be a promising 32 alternative. However, elderly persons have a reduced cutaneous microvasculature, which may 33 affect DBS-based antibody testing. Therefore, we aimed to evaluate the performance of DBS 34 for the detection of SARS-CoV-2 antibodies in nursing homes residents.

35 Materials and methods

We collected venous blood and paired Whatman and EUROIMMUN DBS from nursing home residents, and from staff as a reference population. Venous blood samples were analyzed for the presence of SARS-CoV-2 IgG antibodies using the Abbot chemiluminescent microparticle immunoassay (CMIA). DBS were analyzed by the EUROIMMUN enzyme-linked immuno sorbent assay (ELISA) for SARS-CoV-2 IgG antibodies. We performed a statistical assessment to optimize the ELISA cut-off value for the DBS using the Youden's J index.

42 Results

A total of 273 paired DBS-serum samples were analyzed, of which 129 were positive as
assessed by the reference test. The sensitivities and specificities of DBS ranged from 95.0%
to 97.1% and from 97.1% to 98.8%, respectively, depending on population (residents or staff)
or DBS card type.

47 **Conclusion**

48 DBS sampling is a valid alternative to venipuncture for the detection of SARS-CoV-2 antibodies
49 in the elderly.

- 50
- 51
- 52

53 Keywords

Elderly, nursing homes, SARS-CoV-2, COVID-19, antibodies, immunoglobins, IgG, serology,
dried blood spots (DBS), enzyme-linked immunosorbent assay (ELISA), serosurveillance,
vaccination

57

58 Introduction

In the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic,
large-scale serological antibody studies are paramount to assess the true SARS-CoV-2
infection rate.

62 Indeed, statistics on PCR-confirmed SARS-CoV-2 cases are far from ideal to estimate the true 63 proportion of the population that experienced a SARS-CoV-2 infection (1), as mildly affected 64 or asymptomatic individuals are often not tested and PCR-based testing only yields an 65 epidemiological snapshot. Furthermore, the recent implementation of newly developed SARS-66 CoV-2 vaccines creates an urgent need for population-based serological studies to monitor 67 antibody responses post-authorization. Protocols for SARS-CoV-2 antibody assays using 68 serum/plasma obtained by venipuncture are well established in a clinical setting. However, 69 venipuncture is invasive and can cause serious discomfort. Especially in the elderly, 70 venipuncture poses large challenges due to dehydration, loss of vein patency and low blood 71 pressure. Elderly may also suffer from arthritis, injury or stroke, impeding to hyperextend the 72 arms to survey for available veins. The use of venipuncture is further limited for wider 73 application in non-clinical settings due to the costs (for e.g., phlebotomists), logistical 74 constraints associated with collecting, processing, and transporting venous blood.

Collecting capillary blood on protein saver cards after finger pricking using a lancet, the socalled dried blood spot (DBS), is a most valuable alternative as it is minimally invasive, can be done at low cost, has the potential for self-sampling and is easy to ship and store. DBS are increasingly applied as a minimally invasive alternative for infectious serology, especially in community- and population-based epidemiology, including SARS-CoV-2 (2). However, the use of DBS has not yet been validated for detection of SARS-CoV-2 antibodies in the elderly. Aging is known to modify the cutaneous microvasculature and the structures of blood vessels, even
down to the level of the capillary basement membrane (3). Here, we aimed to validate the use
of DBS sampling for the detection of SARS-CoV-2 IgG antibodies in a population of residents
and staff from nursing homes.

85

86 Methodology

87 Ethical considerations

The current study was approved by the Ethical Committee of the Ghent University Hospital (reference number BC-07665) and conducted according to the principles outlined in the Declaration of Helsinki. Each participant signed an informed consent form after being informed about the goal of the study and the sampling procedures. A confidential counselor, such as a nurse, signed for participants who were incapable to sign the consent form, such as residents with dementia when consent was given by their legal representative.

94

95 Study population

96 In August 2020, we contacted the management of four NHs within our network (Amphora, 97 Wingene; Sint-Rafaël, Liedekerke; Sint-Jozef, Assenede and Sint-Jozef, Wetteren; all in 98 Flanders, Belgium) and explained the goal of the study. We recruited NHs that experienced a 99 SARS-CoV-2 outbreak in the period March to July 2020 in order to increase the likelihood of 100 obtaining seropositive samples, hence minimizing the number of screened participants needed 101 to obtain our sample size. The management informed the families of residents and recruited a 102 total of 199 residents and 241 staff members interested in participating in our study.

103

104 Sample collection

We obtained approximately 5 ml of venous blood from each participant by venipuncture in serum tubes using a 23G scalp vein set. Capillary blood was collected after briefly puncturing the top edge of the distal phalanx of the middle or ring finger using 18G safety lancets (Sarstedt, Numbrecht, Germany) onto Whatman protein saver cards (Whatman[™], GE

109 Healthcare Sciences, Cardiff, UK). During sample collections, the protein saver card of 110 EUROIMMUN (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) was 111 marketed and also evaluated on a subset of participants together with the Whatman protein 112 saver cards. For each protein saver card, a preprinted circle was filled until saturated (i.e., 113 blood was visible on the backside of the card). In order to avoid sampling bias, for half of the 114 participants (i.e., those with an even participant identification number), first a circle was filled 115 on the Whatman protein saver card, and then on the EUROIMMUN protein saver card, while 116 for the other half of the participants (those with an odd number), the opposite was done. 117 Typically, an average of four blood drops were needed to saturate one circle. All blood 118 collections were done under aseptic conditions. DBS were obtained by allowing the capillary 119 blood to air-dry on the protein saver cards for one hour at room temperature.

Serum tubes were transported to the Laboratory of Clinical Microbiology of the Ghent University Hospital (Ghent, Belgium) within six hours after sample collection. Upon arrival, serum tubes were centrifuged at 3000 g for 8 minutes, and tubes were stored at 4 °C. The following day, serum was aliquoted into new serum vials and analyzed by means of Abbott SARS-CoV-2 IgG Architect immunoassay (Abbott Laboratories). DBS selected for analysis (see further) were analyzed maximum two days after collection.

126

SARS-CoV-2 IgG detection in sera by means of chemiluminescent microparticle immunoassay
 (CMIA)

All serum samples were analyzed for anti-nucleocapsid SARS-CoV-2 IgG serology by using the Architect i2000sr Plus system (Abbott). This system allows high-throughput screening of the sera, providing real-time information on the number of positive samples. This way, we could rapidly validate DBS for our ongoing and future studies in NHs. The Architect i2000sr Plus system uses the chemiluminescent microparticle immunoassay (CMIA)-technique to detect antibodies. After thawing the sera and vortexing briefly, the Architect system analyzes the samples automatically using a SARS-CoV-2 assay, a specific calibrator kit and a specific

control kit. We used an in-house validated cut-off index of 0.9 to classify sera as positive (≥0.9)
or negative (<0.9) for SARS-CoV-2 IgG antibodies.

138

139 SARS-CoV-2 IgG detection in dried blood spots by means of ELISA

140 The DBS were analyzed for the presence of anti-spike (S1-antigen) SARS-CoV-2 IgG 141 antibodies by means of ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, 142 Germany), and not the Abbot CMIA, because this assay requires a volume of 150 µl, which is 143 more than the volume of capillary blood absorbed on one circle of the DBS. From each DBS 144 card, one circle of 6 mm diameter was cut out using a puncher and placed into the well of a 145 sterile 96-well U-shaped microtiter plate. To avoid cross-contamination, the puncher was 146 cleaned using a 70% alcohol solution and cotton swab in between punching. A total volume of 147 250 µl preheated (1 hour at 37°C) sample buffer was added to each sample well of the 96-well microtiter plate and incubated at 37 °C for 1 h. After gently mixing the eluate by means of up-148 149 and-down pipetting, a total of 100 µl of this eluate was used for ELISA, according to the 150 manufacturer's instructions. The ELISA was run on the automated Behring Elisa Processor III 151 (SIEMENS AG, Munich, Germany). DBS were classified according to their antibody index 152 optical density (OD) value as negative (<1.1) or positive (\geq 1.1), as recommended by the 153 manufacturer. The borderline category was not considered.

154

155 Sample size and analysis

The sample size was calculated using the methodology described by Buderer (1996), focusing on the sensitivity (4). Here, we hypothesized sensitivity of DBS to be lower compared to sera due to antibodies being affected by or remaining captured in the protein saver cards. Using an anticipated sensitivity of 85%, an α level of 0.05 and a precision parameter (ϵ) of 0.10, we needed a minimum of 49 positive sera, which were collected for both the residents and staff.

161 The sensitivity and specificity of the DBS were calculated using the Abbott CMIA on sera from 162 venous blood as a reference test. The 95% confidence intervals (CI) were calculated using the 163 Wilson-Brown method (5).

- 164 To determine the optimal cut-off value for the Whatman and EUROIMMUN DBS test, we
- 165 calculated Youden's J-index statistic, and the accuracy was calculated using the area under
- 166 the curve (AUC) of the receiver operating characteristic (ROC) curves.
- 167 All analyses were performed using the statistical software GraphPad Prism 6 (GraphPad
- 168 Software Inc., San Diego, U.S.).

169 **Results**

170 In four NHs, a total of 440 paired venous blood - Whatman DBS samples were obtained, of 171 which 199 were from residents and 241 from staff (Figure 1). The sera from these 440 venous 172 blood samples were screened by means of the Abbott IgG CMIA reference assay. Of these 173 samples, 129 samples were found positive (60 residents and 69 staff). The paired Whatman 174 DBS from these positive sera, together with 144 paired Whatman DBS samples from negative 175 sera, were analyzed by means of ELISA. The selection of paired DBS from negative sera 176 included 85 paired samples from residents and 59 from staff. The mean age of residents and 177 staff of which the paired sera-Whatman DBS were analyzed was 87.8 years (range 67-100) 178 and 42.8 years (range 19-65), respectively. A total of 80.0% and 93.8% of residents and staff, 179 respectively, were female. Additionally, a subset of 150 EUROIMMUNE DBS samples were 180 analyzed, of which 82 were found positive (32 residents and 50 staff) by the reference test 181 (Figure 1).



¹⁹³ Figure 1. Schematic figure of the collection, screening and analysis of sera and dried

194 **blood spots.** CMIA, chemiluminescent microparticle immunoassay; DBS, dried blood spot; EI,

- 195 EUROIMMUN; ELISA, enzyme-linked immunosorbent assay; WM, Whatman.
- 196

197 The crosstabs with the number of true/false positives and negatives of the Whatman DBS and 198 EUROIMMUN DBS in comparison with the reference test for all participants and categorized 199 per residents and staff, is shown in Table 1. One of the two false-positive Whatman DBS test 200 results with an optical density (OD) value of 4.39, was obtained from a participant who tested 201 positive (RT-PCR) for SARS-CoV-2 in March 2020, making it unlikely that this DBS 202 seropositivity was false-positive, in contrast, the reference test likely was falsely negative. The 203 sensitivity and specificity of both the Whatman DBS and the EUROIMMUN DBS compared to 204 the Abbott CMIA as a reference test is shown in Table 2.

205

Table 1. The number SARS-CoV-2 IgG true/false positive and true/false negative Whatman (WM) DBS and EUROIMMUN (EI) DBS in comparison to the Abbott CMIA reference test.

- Reference test (CMIA on venous blood) positive negative **DBS WM total** 2 positive 124 negative 142 5 **DBS WM** positive 57 1 84 negative 3 **DBS WM staff** positive 67 1 2 58 negative **DBS EI total** 78 2 positive 66 negative 4 DBS EI 31 1 positive 33 1 negative **DBS EI staff** 47 1 positive 33 negative 3
- 209
- 210
- 211
- 212
- 213

Table 2. Sensitivity and specificity of the Whatman (WM) and EUROIMMUN (EI) dried

	SEN (%)	95% CI	SPE (%)	95% CI
DBS WM total	96.1	91.2-98.7	98.6	95.1-99.8
DBS WM	95.0	86.3-98.6	98.8	93.6-99.9
DBS WM staff	97.1	90.0-99.5	98.3	91.0-99.1
DBS El total	95.1	88.1-98.1	97.1	89.9-99.5
DBS El residents	96.7	84.3-99.8	97.1	85.1-99.9
DBS EI staff	94.0	83.8-98.4	97.1	85.1-99.9

215 blood spot ELISA in comparison with the Abbott CMIA as the reference test^a.

^aCMIA, chemiluminescent microparticle immunoassay; CI, confidence interval; DBS, dried

217 blood spot; EI, EUROIMMUN; SEN, sensitivity; SPE, specificity; WM, Whatman.

218

219 The scatter plot of the index values of the reference test (Abbot CMIA) and the OD values of 220 the ELISA Whatman DBS is shown in Figure 2. The Pearson correlation coefficient for the 221 reference test and the Whatman DBS was 0.80 (95% CI, 0.75 to 0.84) and significant 222 (p<0.0001). The Pearson correlation coefficient for the reference test and the EUROIMMUN DBS was 0.78 (95% CI, 0.73 to 0.82) and significant (p<0.0001) (scatterplot similar to 223 224 reference test versus Whatman DBS, data not shown). A scatter plot showing the correlation 225 between the optical density (OD) values from the 150 paired Whatman and EUROIMMUN DBS 226 is depicted in Figure 2. The Pearson correlation coefficient was found to be 0.970 (95% CI, 227 0.959 - 0.978) and significant (p<0.0001). Of one paired sample, the Whatman DBS showed 228 a positive result (OD 1.41), but not the EUROIMMUN DBS (OD 1.02). However, the latter is 229 classified as borderline when following the manufacturer's guidelines. This category was not 230 considered in the current analysis and classified as negative.



Figure 2. Scatter plot of paired sera and Whatman DBS (left) and Whatman DBS and EUROIMMUN DBS (right) optical density/index values. Axes represent the log10 of the optical density and index values. DBS, dried blood spot; FN, false negatives; FP, false positives; OD, optical density. The grey horizontal and vertical lines represent cutoff lines defining positive samples.

237 To verify if the ELISA Whatman and EUROIMMUN DBS cutoff could be optimized, we 238 performed a ROC analysis. The ROC curves are shown in Figure 3. The area under the curve 239 was 0.999 for both Whatman and EUROIMMUN DBS (95% CI, 0.999 to 1.000) (p<0.0001). 240 The optimal cut-off point for Whatman DBS was found to be 1.14, which is almost exactly the 241 value of 1.1 proposed by the manufacturer of the ELISA assay, and did not improve sensitivity or specificity. The optimal cut-off point for EUROIMMUN DBS was found to be 1.02 and 242 applying this cutoff improved both sensitivity (from 95.1% to 96.4%) and specificity (from 97.1% 243 244 to 98.5%).



246

Figure 3. Receiver operating characteristics (ROC) curve for the evaluation of the

248 Whatman DBS ELISA (left) and EUROIMMUN (right) compared to the reference assay.

The area under the curve is 0.999 for both Whatman and EUROIMMUN DBS (95% CI, 0.999

- 250 to 1.000) (p<0.0001).
- 251

252 **Discussion**

In the present study, we evaluated the use of DBS for detection of SARS-CoV-2 antibodies in residents and staff from nursing homes. To the best of our knowledge, we report the largest clinical DBS validation study, comparing two different DBS samples (Whatman and EUROIMMUN) in a key target population in the current SARS-CoV-2 pandemic, the elderly persons residing in NH.

Overall, we demonstrated a high sensitivity (range 95.0-97.1%) and specificity (range 97.1-98.8%) for DBS compared to sera. Adjustment of the manufacturer recommended cut-off from 1.1 to 1.02 resulted in a slight improvement of sensitivity and specificity for EUROIMMUN DBS only. We found no significant differences in sensitivity or specificity of the DBS between residents and staff, for both Whatman and EUROIMMUN DBS, as demonstrated by the largely overlapping confidence intervals. Furthermore, protein saver cards of Whatman and EUROIMMUN yielded results that were nearly in perfect agreement.

265 Several other studies in different populations, such as health care workers, key workers, 266 athletes and children have evaluated DBS sampling for SAR-CoV-2 antibody testing (6-14). In 267 these studies, similar test characteristics were reported with a sensitivity ranging from 89 up 268 to 100% and a specificity of 100% (7, 10, 11), or, reported a nearly perfect agreement in SARS-269 CoV-2 antibody detection between DBS samples and paired venous blood samples (6, 9, 12-270 14). However, some studies were limited by the lack of serum serology as a reference test (7, 271 8) or the rather limited sample size (i.e., <50 positives as assessed by the reference test) (6, 272 7, 11, 12).

Our findings show an excellent diagnostic performance of DBS, both in the elderly and staff from nursing homes. This supports the use of DBS in large-scale SARS-CoV-2 serosurveillance studies as a valuable alternative to venipuncture, especially in the elderly, where venous blood can be challenging to obtain. In comparison to serological rapid tests, which can also be implemented in large-scale SARS-CoV-2 sero-epidemiological studies, DBS offer higher sensitivity, specificity and the possibility to (semi-)quantitatively asses the antibody response (15). Moreover, DBS have the advantage to collect and store the sample for multiple analyses. In this way, different assays can be used on the same sample, such as antibody
assay directed against different antigens. Yet, DBS have similar advantages as these rapid
tests, as they alleviate the need for health care professionals during sampling and complex
shipment and storage.

284 Especially since the implementation of newly developed SARS-CoV-2 vaccines, serology 285 studies are of increasing importance to fill existing research gaps. Until now, the stability and 286 duration of the antibody response upon vaccination is unknown, however, is important to 287 determine if annual boosting is needed. Secondly, a correct antibody response cut-off value 288 that refers to clinical immunity against SARS-CoV-2 is lacking. Additionally, it is of crucial 289 importance to assess the effectiveness of the vaccines among the general population, which 290 can differentiate from what is measured in standardized clinical trials. In this context, the non-291 invasiveness of the DBS, minimal logistic constraints, excellent test characteristics and the 292 possibility for quantitative assessment bring added value in the conduct of serosurveillance 293 studies.

Our study was limited by the use of CMIA on venous blood samples that assessed nucleocapsid antibodies, and not spike antibodies, which were detected by means of ELISA in DBS. Conflicting results are available concerning the degree of persistence between antibodies directed against the nucleocapsid and spike antigen, however, it is suggested that IgG antibody levels directed against the nucleocapsid antigen wane more rapidly post-infection than those against the spike antigen (16). Nevertheless, this should not impact the sensitivity analysis in the current results, as nucleocapsid antibodies were detected as the reference.

301

302 Funding

303 This study was funded by the Special Research Fund of Ghent University

304 (BOF.COV.2020.0010.01).

305

306

308 Acknowledgements

- 309 The authors wish to thank all residents and their families, staff and management from the
- 310 nursing homes that participated in the study.

312 References

- Roda WC, Varughese MB, Han D, Li MY. 2020. Why is it difficult to accurately predict
 the COVID-19 epidemic? Infect Dis Model 5:271-281.
- 315 2. Tuaillon E, Bollore K, Pisoni A, Debiesse S, Renault C, Marie S, Groc S, Niels C,
- 316 Pansu N, Dupuy AM, Morquin D, Foulongne V, Bourdin A, Le Moing V, Van de Perre
- 317 P. 2020. Detection of SARS-CoV-2 antibodies using commercial assays and
- 318 seroconversion patterns in hospitalized patients. J Infect 81:e39-e45.
- 319 3. Bentov I, Reed MJ. 2015. The effect of aging on the cutaneous microvasculature.
- 320 Microvasc Res 100:25-31.
- 321 4. Buderer NM. 1996. Statistical methodology: I. Incorporating the prevalence of disease
 322 into the sample size calculation for sensitivity and specificity. Acad Emerg Med 3:895323 900.
- Brown LD, Cai TT, DasGupta A. 2001. Interval Estimation for a Binomial Proportion.
 Statistical Science 16:101-133, 33.
- 326 6. Amendola A, Bianchi S, Gori M, Barcellini L, Colzani D, Canuti M, Giacomet V,
- 327 Fabiano V, Folgori L, Zuccotti GV, Tanzi E. 2021. Dried Blood Spot as an Alternative
- 328 to Plasma/Serum for SARS-CoV-2 IgG Detection, an Opportunity to Be Sized to
- Facilitate COVID-19 Surveillance Among Schoolchildren. Pediatr Infect Dis J 40:e46e47.
- 331 7. Karp DG, Danh K, Espinoza NF, Seftel D, Robinson PV, Tsai CT. 2020. A serological
 332 assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood
 333 spots. Sci Rep 10:20188.
- 8. McDade TW, McNally EM, D'Aquila R, Mustanski B, Miller A, Vaught LA, Reiser NL,
- Bogdanovic E, Zelikovich AS, Demonbreun AR. 2020. Enzyme immunoassay for
- 336 SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach
- 337 to facilitate community- and population-based screening. medRxiv
- 338 doi:10.1101/2020.04.28.20081844:2020.04.28.20081844.

339	9.	Moat SJ, Zelek WM, Carne E, Ponsford MJ, Bramhall K, Jones S, El-Shanawany T,
340		Wise MP, Thomas A, George C, Fegan C, Steven R, Webb R, Weeks I, Morgan BP,
341		Jolles S. 2021. Development of a high-throughput SARS-CoV-2 antibody testing
342		pathway using dried blood spot specimens. Ann Clin Biochem 58:123-131.
343	10.	Morley GL, Taylor S, Jossi S, Perez-Toledo M, Faustini SE, Marcial-Juarez E, Shields
344		AM, Goodall M, Allen JD, Watanabe Y, Newby ML, Crispin M, Drayson MT,
345		Cunningham AF, Richter AG, O'Shea MK. 2020. Sensitive Detection of SARS-CoV-2-
346		Specific Antibodies in Dried Blood Spot Samples. Emerg Infect Dis 26:2970-2973.
347	11.	Mulchandani R, Brown B, Brooks T, Semper A, Machin N, Linley E, Borrow R, Wyllie
348		D, Investigators E-HS. 2021. Use of dried blood spot samples for SARS-CoV-2
349		antibody detection using the Roche Elecsys (R) high throughput immunoassay. J Clin
350		Virol 136:104739.
351	12.	Thevis M, Knoop A, Schaefer MS, Dufaux B, Schrader Y, Thomas A, Geyer H. 2020.
352		Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2
353		antibody tests? Drug Test Anal 12:994-997.
354	13.	Toh ZQ, Higgins RA, Anderson J, Mazarakis N, Do LAH, Rautenbacher K, Ramos P,
355		Dohle K, Tosif S, Crawford N, Mulholland K, Licciardi PV. 2021. The use of dried
356		blood spots for the serological evaluation of SARS-CoV-2 antibodies. J Public Health
357		(Oxf) doi:10.1093/pubmed/fdab011.
358	14.	Weisser H, Steinhagen K, Hocker R, Borchardt-Loholter V, Anvari O, Kern PM. 2021.
359		Evaluation of dried blood spots as alternative sampling material for serological
360		detection of anti-SARS-CoV-2 antibodies using established ELISAs. Clin Chem Lab
361		Med 59:979-985.
362	15.	Boum Y, Fai KN, Nikolay B, Mboringong AB, Bebell LM, Ndifon M, Abbah A, Essaka
363		R, Eteki L, Luquero F, Langendorf C, Mbarga NF, Essomba RG, Buri BD, Corine TM,
364		Kameni BT, Mandeng N, Fanne M, Bisseck A-CZ-K, Ndongmo CB, Eyangoh S,
265		Hamadou A. Ouamba JP. Koku MT. Niouom R. Claire OM. Esso L. Epée E. Mballa
303		······································

- 368 clinical, prospective, diagnostic accuracy study. The Lancet Infectious Diseases
- 369 doi:10.1016/S1473-3099(21)00132-8.
- 16. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, Farina A, Campos J,
- Hacker D, Lau K, Bosch B-J, Gonseth Nussle S, Bochud M, D'Acremont V, Trono D,
- 372 Greub G, Pantaleo G. 2021. Changes in SARS-CoV-2 Spike versus Nucleoprotein
- 373 Antibody Responses Impact the Estimates of Infections in Population-Based
- 374 Seroprevalence Studies. Journal of virology 95:e01828-20.
- 375



Figure 1. Schematic figure of the collection, screening and analysis of sera and dried **blood spots.** CMIA, chemiluminescent microparticle immunoassay; DBS, dried blood spot; EI, EUROIMMUN; ELISA, enzyme-linked immunosorbent assay; WM, Whatman.



Figure 2. Scatter plot of paired sera and Whatman DBS (left) and Whatman DBS and **EUROIMMUN DBS (right) optical density/index values**. Axes represent the log10 of the optical density and index values. DBS, dried blood spot; FN, false negatives; FP, false positives; OD, optical density. The grey horizontal and vertical lines represent cutoff lines defining positive samples.



Figure 3. Receiver operating characteristics (ROC) curve for the evaluation of the Whatman DBS ELISA (left) and EUROIMMUN (right) compared to the reference assay. The area under the curve is 0.999 for both Whatman and EUROIMMUN DBS (95% CI, 0.999 to 1.000) (p<0.0001).